BIO Releases Principles on Clinical Trial Data Sharing - Applied Clinical Trials


See our 2013 Buyers Guide Digital Edition.
BIO Releases Principles on Clinical Trial Data Sharing

Source: Company News Release

TheBiotechnology Industry Organization (BIO) today reaffirmed and broadened its long-standing commitment to improving human health through the development of innovative therapies by releasing Principles on Clinical Trial Data Sharing, which were adopted by its Health Section Governing Board.

The following statement may be attributed to BIO President and CEO Jim Greenwood:

“BIO recognizes that responsible clinical trial data sharing advances public health and scientific discourse, honors research participants’ expectations of privacy through informed consent, and promotes biomedical innovation.

"These Principles reflect our support for these goals, while maintaining incentives to invest in biomedical research and recognizing the human and financial resource constraints of small, pre-revenue enterprises.

“Our members currently share research data in a number of ways, routinely publishing their clinical trials in peer-reviewed scientific journals and presenting their results at scientific meetings and workshops.

“These Principles reaffirm our support for these efforts, and represent a commitment to make additional information available to the public, qualified researchers, and patients participating in clinical trials.

“We believe these Principles will enhance scientific knowledge to advance public health and patient care. We remain committed to working with the broader scientific community to develop knowledge that will improve drug development, enhance public health, and reinforce public confidence in the safety and efficacy of our medicines.”

For more information on the biotech industry, please visit


blog comments powered by Disqus



8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
View Results
Untitled Document
Source: Company News Release,
Click here